These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23837762)

  • 1. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.
    Kao HF; Lin CC; Yang JC
    Future Oncol; 2013 Jul; 9(7):991-1003. PubMed ID: 23837762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
    Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
    Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
    Soria JC; Mok TS; Cappuzzo F; Jänne PA
    Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.
    Costanzo R; Montanino A; Di Maio M; Piccirillo MC; Sandomenico C; Giordano P; Daniele G; Franco R; Perrone F; Rocco G; Normanno N; Morabito A
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1207-18. PubMed ID: 24134422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.
    Gorden KJ; Mesbah P; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):245-9. PubMed ID: 21733906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
    Zhang WQ; Li T; Li H
    Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib in the first-line treatment of non-small-cell lung cancer.
    D'Arcangelo M; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 May; 13(5):523-33. PubMed ID: 23617344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
    Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
    Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
    Pircher A; Manzl C; Fiegl M; Popper H; Pirker R; Hilbe W
    Lung Cancer; 2014 Mar; 83(3):408-10. PubMed ID: 24412619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi A; Pasquale R; Esposito C; Normanno N
    Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
    Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.